Insider Trading Alert - CME, CIM And REGN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 14, 2014, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $95.00 to $17,134,950.00.

Highlighted Stocks Traded by Insiders:

CME Group (CME) - FREE Research Report

Pankau Ronald A., who is Director at CME Group, sold 400 shares at $73.65 on Aug. 14, 2014. Following this transaction, the Director owned 3,662 shares meaning that the stake was reduced by 9.85% with the 400-share transaction.

The shares most recently traded at $73.60, down $0.05, or 0.07% since the insider transaction. Historical insider transactions for CME Group go as follows:

  • 4-Week # shares sold: 3,767
  • 12-Week # shares bought: 350
  • 12-Week # shares sold: 3,767
  • 24-Week # shares bought: 350
  • 24-Week # shares sold: 5,767

The average volume for CME Group has been 1.4 million shares per day over the past 30 days. CME Group has a market cap of $24.7 billion and is part of the financial sector and financial services industry. Shares are down 6.27% year-to-date as of the close of trading on Thursday.

CME Group Inc., through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. The stock currently has a dividend yield of 2.56%. The company has a P/E ratio of 25.7. Currently, there are 7 analysts who rate CME Group a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CME - FREE

TheStreet Quant Ratings rates CME Group as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full CME Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Chimera Investment (CIM) - FREE Research Report

Colligan Robert S, who is Chief Financial Officer at Chimera Investment, bought 30,000 shares at $3.21 on Aug. 14, 2014. Following this transaction, the Chief Financial Officer owned 30,000 shares meaning that the stake was boosted by 100% with the 30,000-share transaction.

The shares most recently traded at $3.26, up $0.05, or 1.53% since the insider transaction.

The average volume for Chimera Investment has been 5.2 million shares per day over the past 30 days. Chimera Investment has a market cap of $3.3 billion and is part of the financial sector and real estate industry. Shares are up 3.87% year-to-date as of the close of trading on Thursday.

Chimera Investment Corporation operates as a real estate investment trust (REIT) in the United States. The stock currently has a dividend yield of 11.18%. The company has a P/E ratio of 9.8. Currently, there are no analysts who rate Chimera Investment a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CIM - FREE

TheStreet Quant Ratings rates Chimera Investment as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Chimera Investment Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Goldstein Joseph L, who is Director at Regeneron Pharmaceuticals, sold 2,000 shares at $347.65 on Aug. 14, 2014. Following this transaction, the Director owned 6,000 shares meaning that the stake was reduced by 25% with the 2,000-share transaction.

The shares most recently traded at $348.90, up $1.25, or 0.36% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares bought: 255
  • 4-Week # shares sold: 13,646
  • 12-Week # shares bought: 255
  • 12-Week # shares sold: 13,646
  • 24-Week # shares bought: 255
  • 24-Week # shares sold: 13,646

The average volume for Regeneron Pharmaceuticals has been 853,100 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $34.0 billion and is part of the health care sector and drugs industry. Shares are up 24.64% year-to-date as of the close of trading on Thursday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 97.5. Currently, there are 8 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Trades Above 25,000 as U.S.-China Trade Tensions Thaw

Dow Trades Above 25,000 as U.S.-China Trade Tensions Thaw

Treasury Secretary Mnuchin: 'Take the Over' on U.S. GDP Topping 3% This Year

Treasury Secretary Mnuchin: 'Take the Over' on U.S. GDP Topping 3% This Year

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Video: Why the Stock Market Is Discounting China Trade Fears for Now

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec